Press review
The essentials of recent medical publications, unpacked by our newsroom into a clear, sourced digest, specialty by specialty.
Urology-nephrologyProstate cancer: could physical exercise be the key to regaining an active sexual life?
By Lila Rouland | Published on November 21, 2025 | 3 min readSexual dysfunction is a common side effect of prostate cancer treatments, impacting patients’ quality of life well beyond the acute phase of disease. Despite pharmacological progress, current therapeutic approaches often fail to sufficiently address the physical, psychological, and relational components involved. This highlights the need
OncologyDigital rectal exam in prostate cancer screening: time to rethink its role?
By Carolina Lima | Published on November 20, 2025 | 3 min readThe digital rectal exam (DRE) has historically been a key tool in the early detection of prostate cancer (PCa). Before the widespread use of prostate-specific antigen (PSA) testing, DRE was the primary method for identifying potentially aggressive tumors. PSA transformed early detection by identifying cancers even in asymptomatic men, l
Urology-nephrologyProstatectomy or SBRT: which treatment better preserves quality of life?
By Lila Rouland | Published on November 20, 2025 | 3 min readIn men with localized prostate cancer at low or intermediate risk, two curative treatments are now standard options: radical prostatectomy and stereotactic body radiotherapy (SBRT). While surgery is often regarded as the more radical approach, radiotherapy is considered less invasive, but its side effects—particularly bowel toxicity—rais
OncologyCan physical exercise improve quality of life in patients with metastatic castration-resistant prostate cancer?
By Lila Rouland | Published on November 19, 2025 | 3 min readMetastatic castration-resistant prostate cancer (mCRPC) represents an advanced stage of the disease, commonly treated with androgen deprivation therapy (ADT). Although this strategy improves survival, it often leads to a deterioration in quality of life (QoL), with side effects such as fatigue, cognitive impairment, bone pain, and urinar
OncologyHow are new therapies transforming the management of metastatic castration-resistant prostate cancer?
By Lila Rouland | Published on November 18, 2025 | 3 min readMetastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease despite a decade of significant therapeutic progress. The clinical objective is no longer limited to survival, but now also includes quality of life (QoL) and symptom control. The biological heterogeneity of mCRPC, marked by increasing genomic complexity
Urology-nephrologyTreatment of prostate cancer with GnRH agonists: what is the real impact on quality of life?
By Lila Rouland | Published on November 17, 2025 | 3 min readProstate cancer is one of the most common cancers in men. In advanced stages, treatment often relies on hormone therapy using GnRH (gonadotropin-releasing hormone) agonists. While this approach slows tumor progression by suppressing testosterone, it also causes significant side effects that may impair quality of life (QoL). Fatigue, mood
OncologyCan the tumor transcriptomic profile predict immunotherapy efficacy?
By Lila Rouland | Published on November 14, 2025 | 2 min readThe emergence of immunotherapies, particularly immune checkpoint inhibitors (ICIs), has revolutionized the management of many cancers. However, only a minority of patients derive durable benefit. Current biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have significant limitations i
OncologyIs early therapeutic intensification the key to treating metastatic castration-sensitive prostate cancer?
By Lila Rouland | Published on November 13, 2025 | 4 min readMetastatic castration-sensitive prostate cancer (mCSPC) remains a major public health challenge for men worldwide. Historically, its management relied on androgen deprivation therapy (ADT) alone. However, advances in understanding the androgen receptor (AR) signaling pathway have profoundly changed therapeutic strategies. The early integ
OncologyDarolutamide, undetectable PSA, and prolonged survival: a new standard in prostate cancer treatment?
By Lila Rouland | Published on November 12, 2025 | 3 min readMetastatic hormone-sensitive prostate cancer (mHSPC) is undergoing a therapeutic revolution with the introduction of intensified combination regimens incorporating darolutamide. The ARASENS study, which demonstrated a survival benefit with the addition of darolutamide to androgen deprivation therapy (ADT) and docetaxel, has redefined the
OncologyDarolutamide: Will it redefine the initial treatment strategy in metastatic prostate cancer?
By Lila Rouland | Published on November 12, 2025 | 3 min readFor many years, metastatic castration-sensitive prostate cancer (mCSPC) was treated exclusively with androgen deprivation therapy (ADT). However, recent therapeutic advances have led to the emergence of combination strategies, particularly those involving androgen receptor signaling inhibitors (ARSi). Among these agents, darolutamide, al
OncologyEnzalutamide in mHSPC: Equal efficacy and tolerance after 75 years of age?
By Lila Rouland | Published on November 10, 2025 | 4 min readMetastatic hormone-sensitive prostate cancer (mHSPC) represents a major therapeutic challenge, particularly in older patients who are frequently underrepresented in clinical trials due to comorbidities, physiological frailty, or concerns about increased adverse effects. Yet, over 65% of prostate cancer–related deaths occur in men aged 75
OncologyDoes the circulating tumor cell count predict survival in metastatic hormone-sensitive prostate cancer?
By Lila Rouland | Published on November 10, 2025 | 3 min readMetastatic hormone-sensitive prostate cancer (mHSPC) is a clinical entity in which combination therapies have significantly improved overall survival. However, despite these advances, interindividual variability in treatment response remains high, making it difficult to identify patients at high risk of progression. Given this heterogene